At a glance
ClinicalIndex Comparison RecordN/ACompleted· 29 enrolled
Drug / intervention
Flexitouch Plus with Cellular Connectivity (FT-CC)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Feasibility Study Evaluating the Impact Flexitouch Plus With Connectivity Has on Compliance in Patients With Breast Cancer-Related Lymphedema (BCRL)
In Brief
A clinical study evaluating Flexitouch Plus with Cellular Connectivity (FT-CC) for Breast Cancer Lymphedema. Completed, enrolled 29 participants across 3 sites.
Detailed Summary
The objective of this study is to demonstrate the feasibility of using the Flexitouch Plus with Cellular Connectivity (FT-CC) to monitor device use data to determine if reminders to patients impact compliance, and to identify the impact device compliance has on arm girth, quality of life (QOL), and symptom assessment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer Lymphedema
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartAug 2020
Primary CompletionNov 2021
TodayJul 2026
First PostedJun 16, 2020
Enrollment StartAug 13, 2020
Primary CompletionNov 19, 2021
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.0 years ago
Interventions
Flexitouch Plus with Cellular Connectivity (FT-CC)device
Daily use of FT-CC